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Background: Longer duration of untreated psychosis (DUP) is associated with poorer outcome in terms of
positive symptoms, relapse rate, and time to remission. In contrast, the association with negative symptoms
is less consistent.
Aims: The study had three aims. First, to arrive at a more precise estimate of the correlation between
DUP and negative symptoms than previous reviews, by substantially increasing the amount of avail-
able data. Second, to see whether the strength of this correlation attenuated over longer follow-up
intervals. Third, to determine whether there is a relationship between DUP and changes in negative
symptoms.
Method: Relevant databases were searched for studies published between December 1992 and March
2009 that reported data on DUP and negative symptoms. We obtained individual patient data where
possible and calculated summary correlations between DUP and negative symptoms for each study at
baseline, short and long-term follow-up. We used multilevel regression analysis to examine whether
the effect of DUP on negative symptoms was the greatest in the early stages of illness.
Results:We included 28 non-overlapping studies from the 402 papers detected by the search strategy. After
contacting the authors we obtained individual patient data from 16 of these studies involving 3339 partic-
ipants. The mean DUP was 61.4 weeks (SD=132.7, median DUP=12.0). Shorter DUP was signiﬁcantly as-
sociated with less severe negative symptoms at baseline and also at short (1–2 years) and longer term
follow-up (5–8 years) (r=0.117, 0.180 and 0.202 respectively, pb0.001). The relationship between im-
provement in negative symptoms and DUP was found to be non-linear: people with a DUP shorter than
9 months showed substantially greater negative symptom reduction than those with a DUP of greater
than 9 months.
Conclusions: Shorter DUP is associated with less severe negative symptoms at short and long-term follow
up, especially when the DUP is less than 9 months. Since there is no effective treatment for negative symp-
toms, reducing DUP to less than 9 months may be the best way to ameliorate them.© 2012 Elsevier B.V. All rights reserved.1. Introduction
Negative symptoms are a core component of the schizophrenia
syndrome and are commonly described in terms of ﬁve dimensions:
blunted affect, alogia, anhedonia, avolition and asociality (Blanchardare Service, PO Box 932,
2848989; fax: +599 3158
Boonstra).
rights reserved.et al., 2005; Kirkpatrick et al., 2006; Makinen et al., 2008). Negative
symptoms are associated with poor functional outcome (Malla et al.,
2004), cognitive deﬁcits (Heydebrand et al., 2004), social dysfunction
and poor quality of life (Addington and Addington, 1993; Schmitz
et al., 2007; Petersen et al., 2008). Negative symptoms are common:
the prevalence in short-term follow-up studies (up to 2.5 years) is
about 45% (Pogue-Geile and Harrow, 1985; Malla et al., 2002, 2004),
and in longer term studies (7.5–10 years) 20–30% (Herbener and
Harrow, 2001).
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toms (Kirkpatrick et al., 2006; Buckley and Stahl, 2007). Pharmaco-
logical treatments, such as antipsychotics have only a marginal
impact on negative symptom severity (Leucht et al., 2011). Some
psychosocial treatment trials have shown an effect on negative
symptoms. Cognitive behavioral therapy showed a positive effect
on negative symptoms up to 24 months of follow-up (NICE,
2010). In addition there have been three small but promising trials
on peer support groups (Castelein et al., 2008), music therapy
(Gold et al., 2009) and body oriented psychosocial therapy
(Rohricht and Priebe, 2006).
Pending replication of these studies, it may be that the best way to
deal with negative symptoms apart from cognitive therapy is preven-
tion. Many countries have already adopted an early intervention
approach to the treatment of psychosis on the basis that there is a
robust association between duration of untreated psychosis and the
long-term severity of positive symptoms. A similar association be-
tween negative symptoms and outcome would support early inter-
vention for negative symptoms (Melle et al., 2008).
So far two meta-analyses have examined the correlation be-
tween DUP and negative symptoms (Marshall et al., 2005;
Melle et al., 2008). The ﬁrst by Marshall et al. reported an asso-
ciation at 6 and 12 months but not at baseline and 24 months
(Marshall et al., 2005). The second by Perkins et al. claimed
that patients with shorter DUP experienced less negative symp-
toms at baseline and follow-up (Perkins, 2006). While making
a valuable contribution, both reviews share three limitations.
First, neither study provided a precise analysis of the effect of
DUP at long term follow-up, thus Marshall et al. did not consider
data on negative symptoms beyond 24 months and Perkins et al.
summarized data of all follow-up assessments varying from
3 months to 15 years into one combined effect size. Second,
both studies relied exclusively on published data, which meant
that they excluded a substantial number of studies that collected
pertinent data but did not publish it in a format that could be
used in their analyses. Third, both studies used combined corre-
lation coefﬁcients calculated by different techniques, for example
parametric in some studies and non-parametric in others.
As a consequence of these limitations, neither study was able to
consider the relationship over time i.e. the linearity of the relation-
ship between DUP and negative symptoms. So far most studies did
focus on the relationship between DUP and positive symptoms
(Drake et al., 2000). Not only a positive association was found in
most studies but also a non-linearity of this relationship between
DUP and positive symptoms. This means that in a patient with a
DUP of less than 12 months, the effect of a DUP reduction of for ex-
ample 2 months on positive symptoms would be greater than a
two month reduction in someone with a DUP of more than
12 months. It is possible therefore that a similar non-linear relation-
ship might exist with negative symptoms, with important clinical
implications.
The present study therefore had three aims: (a) to provide a pre-
cise estimate of the correlation between DUP and negative symp-
toms by substantially increasing the amount of available data
contributing to the analysis; (b) to see if the strength of any correla-
tion attenuates at longer follow up intervals; (c) to determine




The search aimed to detect all cohort studies that had examined
DUP and negative symptoms in ﬁrst episode psychotic patients, and
were available for review up to March 2009. The search includedthe databases MEDLINE and PUBMED using the keywords “DUP”
AND “psychosis” OR “schizophrenia” and the combination “duration”
AND “untreated” AND “psychosis” OR “schizophrenia”. In addition
references cited in these papers were examined.
2.2. Inclusion criteria and data extraction
Studies were included if they met two criteria. First, partici-
pants had experienced a ﬁrst episode of psychosis deﬁned as:
schizophrenia, schizoaffective disorder, schizophreniform disorder,
delusional disorder, brief psychotic disorder or psychosis NOS,
according to either the Diagnostic Statistical Manual (DSM-IV) or
the International Classiﬁcation of Diseases (ICD-10) classiﬁcation
systems. Second, DUP and negative symptoms had been measured
using a standardized method (which for negative symptoms was
one of the three commonly used scales in this area), i.e.: the Posi-
tive and Negative Symptom Scale (PANSS) (Kay et al., 1987), the
Scale for the Assessment of Negative Symptoms (SANS)
(Andreasen, 1989), or the Brief Psychiatric Rating Scale (BPRS)
(Overall and Gorham, 1962). We included all follow-up studies re-
gardless of research design.
Abstracts were screened independently by two reviewers
(N.B. and R.K.), and copies were obtained of any papers describ-
ing potentially eligible studies. Each paper was assessed indepen-
dently by two reviewers and any disagreements resolved by
discussion with a third reviewer (L.W.) (for table of included
studies see Appendix 1). To overcome the limitations of previous
meta-analyses it was necessary to obtain a substantial dataset of
individual patient data (IPD) from ﬁrst-episode studies (Stewart
and Parmar, 1993; Stewart and Tierney, 2002). The authors of in-
cluded studies were contacted and asked to provide anonymized
individual patient data on: gender, age at onset, DUP, and nega-
tive symptom scores at baseline and all available follow-up
points.
2.3. Analysis
We calculated the correlation between DUP and negative symp-
toms for short and long term follow up. We deﬁned short-term fol-
low up as between 12 and 24 months and long term follow up as
60 to 96 months. Studies of which a Spearman correlation was
published were used for sensitivity analysis.
In cases where more than one assessment was available for short or
long term follow up, we used the ﬁrst assessment. The data were ana-
lyzed using a two-step approach. First, individual patient data from
each study were analyzed using the non-parametric Spearman's Rank
Correlation.We choose a non-parametric test because of the signiﬁcant
positive skew in the distribution of DUP. In the second step, a
meta-analysis of the aggregated data produced for each study was
performed using Comprehensive Meta‐Analysis in order to summarize
the correlations (CMA, version 2005, Biostat, Inc., Englewood, NJ,
2005) (Borenstein et al., 2009).We used random effect models because
of great differences between research designs. Correlation data were
synthesizedwith Fisher's z transformation into a single correlation coef-
ﬁcient (r) with 95% conﬁdence intervals (CI).
CMA also tests for the heterogeneity of the sample populations
using I2, a test parameter, which evaluates the null hypothesis that
all studies are assessing the same effect size. I2 indicates the percent-
age of total variation across studies due to heterogeneity rather than
chance, and ranges from 0% (no heterogeneity) to 100% (high het-
erogeneity). Values for I2 of 25%, 50% and 75% are considered to rep-
resent low, moderate and high heterogeneity respectively (Higgins
et al., 2003).
Amajor concernwhen conducting ameta-analysis is publication bias:
studies that report relatively large effect sizes are more likely to be pub-
lished than studies with smaller effect sizes. If the included studies are a
14 N. Boonstra et al. / Schizophrenia Research 142 (2012) 12–19biased sample of all relevant studies, consequently the bias will be
reﬂected in the mean effect computed by the meta-analysis. A funnel
plot can be made to examine the publication bias using Comprehensive
Meta-Analysis (CMA, version 2005, Biostat, Inc., Englewood, NJ, 2005).
We examined the linearity of the relationship between DUP and neg-
ative symptom change using the method developed by Drake (Drake
et al., 2000). We used a multilevel regression analysis (XTREG in
STATA release 11.0) (Snijders and BRJ, 1999; StataCorp., 2009) to esti-
mate the magnitude of the effect of DUP on negative symptom severity
reduction after various periods of follow-upwith the individuals nested
within each study. Subsequently, explanatory variables (gender and age
at onset) were added, as potential confounders. The skewed distribu-
tion of DUP was corrected by converting DUP to its logarithm (logDUP)
thus allowing the use of parametric statistics. The change of negative
symptoms from baseline to follow-up was calculated as a percentage
of baseline negative symptom severity and added in the multilevel re-
gression analysis as the dependent variable. We conducted the analysis
for negative symptom change at short and long-term follow up, as de-
ﬁned above.
3. Results
3.1. Studies and patients
A total of 402 papers were identiﬁed by the search strategy,
from which we identiﬁed 28 non-overlapping ﬁrst episodeTable 1
Summary of the 16 included ﬁrst episode studies.
Study inclusion period N
baseline
Gender Age at onset (SD
M F M F
Addington (Addington et al., 2004)
(Jan. 1997–Dec. 2000)
240 161 79 23.4 (6.7) 2
Barnes (Barnes et al., 2000)
(Feb 1995–Oct 2001)
98 75 23 23.5 (6.6) 2
Chen (Chen et al., 2005)
(Sept. 1997–March 2000)
93 42 51 29.0 (9.2) 3
Clarke (Clarke et al., 2006)
(Febr.1995–Febr. 1999)
152 96 56 27.8 (6.4) 2
Craig (Craig et al., 2000)
(1989–1995)
354 194 160 28.6 (15.8) 3
Cullberg (Cullberg et al., 2002)
(Jan. 1996–Dec. 1997)
175 97 78 25.3 (6.4) 2
Drake (Drake et al., 2000)
(July 1996–aug. 1998)
255 176 79 28.0 (9.9) 3
Gorna (Gorna et al., 2008)
(1988–2002)
86 34 52 26.6 (7.0) 2
Harris (Harris et al., 2005)
(March 1989–July 1997)
318 216 102 21.7 (4.1) 2
Malla (Malla et al., 2007)
(January 1997–July 2003)
153 116 37 22.8 (7.2) 2
Manchanda (Manchanda et al., 2005)
(May 1996–Dec. 2001)
122 93 29 22.1 (6.3) 2
Melle (Melle et al., 2004)
(Jan.1997–Dec.2000)
301 176 125 25.1 (7.9) 2
Montague (Montague et al., 1989)
(1986–1988)
109 51 58 26.7 (6.8) 2
Petersen (Petersen et al., 2005)
(Jan. 1998–Dec. 2000)
578 235 343 24.3 (6.6) 2
Ucok (Ucok et al., 2006)
(>1996)
148 84 64 23.3 (6.2) 2
Wunderink (Wunderink et al., 2006)
(Okt. 2001–Dec. 2002)
157 113 44 25.6 (6.0) 2
Overall 3339 1959 1380 25.0 (8.6) 2
M = male.
F = female.studies that met inclusion criteria (see Appendix 1)
(Montague et al., 1989; Barnes et al., 2000; Craig et al., 2000;
de Haan et al., 2000; Drake et al., 2000; Ho et al., 2000;
Larsen et al., 2000; Black et al., 2001; Verdoux et al., 2001;
Cullberg et al., 2002; Malla et al., 2003; Addington et al.,
2004; Sim et al., 2004; Chen et al., 2005; Harris et al., 2005;
Manchanda et al., 2005; Melle et al., 2005; Oosthuizen et al.,
2005; Petersen et al., 2005; Wade et al., 2005; Clarke et al.,
2006; Ucok et al., 2006; Wunderink et al., 2006;
Crespo-Facorro et al., 2007; Malla et al., 2007; Vyas et al.,
2007; Gorna et al., 2008; Yamazawa et al., 2008). The selected
studies included a total of 3998 participants. Following written
requests, authors of 16 studies submitted their data sets that
covered a total of 3339 participants. From the 12 studies of
which individual patient data were not available, 2 studies
reported a Spearman correlation at short term follow-up
(1–2 years). Table 1 shows the distribution of DUP, gender
and age at onset of participants of whom individual patient
data were available at baseline. The follow-up data of 2 studies
were incomplete and therefore only baseline data were used in our anal-
ysis (Montague et al., 1989; Malla et al., 2003; Melle et al., 2004;
Manchanda et al., 2005; Malla et al., 2007).
The mean age at onset of participants was 26.0 years (SD=
8.9), and the mean DUP was 61.4 weeks (SD=132.7 weeks, me-







N at short term
follow-up
(12–24 months)
N at long term
follow-up
(60–96 months)
6.4 (10.3) 77.1 (134.0) 26.0 199 50
7. 2 (8.3) 54.0 (88.1) 20.0 96 –
3.0 (9.7) 44.4 (135.7) 25.7 93 –
6.6 (8.3) 71.0 (115.9) 23.6 – 94
0.3 (11.9) 66.4 (186.2) 3.6 258 –
9.4 (7.1) 66.4 (163.2) 3.6 – 122
–
2.2 (10.7) 38.7 (82.2) 12.0 182 –
3.6 (4.6) 40.4 (57.0) 12.9 83 74
3.9 (5.2) 24.1 (50.1) 5.8 295 135
8.9 (12.0) 70.9 (110.3) 23.9 – –
8.8 (11.2) 70.7 (120.6) 21.6 122 –
9.4 (11.2) 47.4 (117.7) 9.0 271 –
8.1 (8.3) 28.9 (88.1) 20.0 – –
4.5 (6.1) 106.0 (177.2) 34.4 394 247
5.6 (9.3) 32.8 (39.5) 17.1 54 –
8.8 (7.2) 46.0 (111.6) 4.4 120 105
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negative symptoms
Fig. 1 shows a summary of the correlations between DUP
and negative symptoms at baseline and short (1–2 years) and
long-term follow-up (5–8 years). The data show a statistically
signiﬁcant positive correlation between DUP and negative
symptoms at baseline (Fisher's z=0.117, 95%CI 0.064–0.17),
at short-term follow-up (Fisher's z=0.18, 95%CI 0.086–0.274)
and at long-term follow-up (Fisher's z=0.202, 95%CI 0.137−
0.267). There is no evidence for attenuation in the strength of
the association with longer follow up. Tests for heterogeneity
showed that the studies were low to moderately heterogeneous
(I2=48% at baseline, 75.9% at short term, 27.3% at long term
follow-up). A sensitivity analysis was done by adding the
reported Spearman correlations to the meta-analysis at short
term follow-up from the two studies of which individual pa-
tient data were not obtained (Sim et al., 2004; Oosthuizen et
al., 2005; Subramaniam et al., 2007). These two additionalStudy name Statistics for each study
Fisher's Standard Lower Upp
Z error Variance limit lim
Addington (2004) 0,040 0,066 0,004 -0,088 0,1
Barnes (2000) -0,017 0,103 0,011 -0,219 0,1
Chen (2005) -0,057 0,105 0,011 -0,264 0,1
Clarke (2006) -0,029 0,083 0,007 -0,192 0,1
Craig (2000) 0,302 0,054 0,003 0,197 0,4
Cullberg (2002) 0,129 0,089 0,008 -0,045 0,3
Drake (2000) 0,061 0,063 0,004 -0,063 0,1
Gorna (2008) 0,254 0,110 0,012 0,038 0,4
Harris (2005) 0,186 0,056 0,003 0,076 0,2
Malla (2007) 0,145 0,083 0,007 -0,018 0,3
Manchanda (2005) 0,076 0,092 0,008 -0,104 0,2
Melle (2004) 0,122 0,059 0,003 0,007 0,2
Montague (1989) 0,276 0,098 0,010 0,084 0,4
Petersen (2005) 0,053 0,061 0,004 -0,067 0,1
Ucok (2006) 0,063 0,104 0,011 -0,141 0,2
Wunderink (2006) 0,184 0,081 0,007 0,025 0,3
0,117 0,027 0,001 0,064 0,1
correlation between DUP and negative
Study name Statistics for each study
Fisher's Standard Lower Upp
Z error Variance limit lim
Addington (2004) 0,125 0,073 0,005 -0,018 0,2
Barnes (2000) 0,263 0,103 0,011 0,061 0,4
Chen (2000) 0,324 0,105 0,011 0,117 0,5
Craig (2000) -0,062 0,063 0,004 -0,185 0,0
Gorna (2008) 0,175 0,111 0,012 -0,043 0,3
Harris (2005) 0,412 0,056 0,003 0,301 0,5
Manchanda (2005) 0,218 0,092 0,008 0,038 0,3
Melle (2004) 0,227 0,062 0,004 0,105 0,3
Petersen (2005) 0,127 0,048 0,002 0,032 0,2
Ucok (2006) -0,105 0,136 0,019 -0,372 0,1
Wunderink (2006) 0,224 0,092 0,009 0,042 0,4
0,180 0,048 0,002 0,086 0,2
correlation between DUP and negative sym
Study name Statistics for each study
Fisher's Standard Lower Upp
Z error Variance limit lim
Addington (2004) 0,438 0,146 0,021 0,152 0,7
Clarke (2000) 0,258 0,104 0,011 0,053 0,4
Cullberg (2002) 0,040 0,101 0,010 -0,157 0,2
Gorna (2008) 0,293 0,118 0,014 0,062 0,5
Harris (2005) 0,217 0,056 0,003 0,107 0,3
Petersen (2005) 0,160 0,048 0,002 0,066 0,2
Wunderink (2006) 0,219 0,099 0,010 0,025 0,4
0,202 0,033 0,001 0,137 0,2
correlation between DUP and negative symp
Fig. 1. Correlations between DUP and negative symptoms at basestudies did not substantially alter the reported correlations of
heterogeneity statistics (I2=71.8%).
5. Predicted negative symptom change
2150 patients nested in 12 studies were included in the
multilevel analysis to explore the effect of DUP on negative symptom
reduction at short-term follow-up. The mean follow-up assessment
was 15.5 months (95%CI 15.3–15.7). In the multilevel analysis for
long-term follow-up, 795 individuals nested in 7 studies were in-
cluded and the mean follow-up assessment was 71.4 months
(95%CI 70.2–72.7).
Figs. 2 and 3 show the percentage change innegative symptomspre-
dicted by a given DUP at short and long-term follow-up respectively.
6. Discussion
The analysis showed that there is a signiﬁcant positive associa-
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Fig. 3. Predicted change in negative symptoms after longer term, follow-up
(5–8 years) against duration of untreated psychosis in weeks (with 95% CIs).
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non-linear: negative symptoms and DUP are positively associated if
DUP was less than 9 months. For those patients with a DUP longer
than 9 months negative symptoms are not associated linearly. A re-
duction in DUP in someone with a shorter DUP (i.e. less than
9 months) might therefore have a greater impact on negative symp-
toms than the same reduction in someone with a DUP greater than
nine months. These ﬁndings are in accordance with the ﬁndings of
the TIPS study and the study of Malla et al. (2002, 2004), both of
which suggested that reduction of DUP may be as important for im-
proving the severity of negative symptoms as it is for positive symp-
toms (Melle et al., 2008). Our ﬁnding of a non-linear association
between DUP and negative symptoms is similar to that reported by
Drake et al. for total PANSS scores (Drake et al., 2000) albeit in a
small sample with a short follow-up.
The association between a longer DUP and persistence of negative
symptoms (after 1–2 years) is consistent with the hypothesis that in
many cases psychosis is a clinical manifestation of a progressive
pathological process in which early detection and intervention
could be effective in ameliorating the course of the disorder. Figs. 2
and 3 suggest the existence of a critical period of DUP of about
9 months in which the associationwith negative symptoms is partic-
ularly strong. This ﬁnding supports arguments for early detection
and intervention programs, since apart from prevention, there is no
evidence-based treatment for negative symptoms (Melle et al.,
2008). However, it is important to emphasize that this analysis
does not prove that there is a causal association between DUP and
negative symptoms.
An important strength of this study is the use of individual pa-
tient data (IPD). The use of IPD in meta-analyses (Stewart and
Parmar, 1993; Stewart and Tierney, 2002) offers a greater resolu-
tion of effect size than meta-analyses based on study level data. In-
dividual patient data permitted us to reanalyze all the data using
the same method of correlation and to calculate correlations that
had not been previously published. We were also able to combine
data across studies to explore the relationship between DUP and
negative symptoms.
As a result of obtaining individual patient data, this review has
substantially increased the amount of information available for anal-
ysis. Consequently, it has extended the ﬁndings of previous
meta-analyses by providing more precise estimates of the correla-
tion between duration of untreated psychosis and negative symp-
toms, examining the correlation at both short and long-term follow
up and exploring the linearity of the association. This is of clinical im-
portance because the window of opportunity to intervene to im-
prove the prognosis of psychosis is considered to last 3–5 years
(Birchwood, 2000).
The main limitation of the review is that data were obtained on














































Fig. 2. Predicted change in negative symptoms after short term, follow-up (1–2 years)
against duration of untreated psychosis in weeks (with 95% CIs).659 patients. Three studies reported correlations between DUP and
negative symptoms at 12 to 24 months of follow-up of which 2
were Spearman correlations. Adding data of these two studies in
the meta-analysis did not substantially alter the reported correla-
tions of heterogeneity statistics. We were not able to correct for pos-
sible confounding variables on the correlation between DUP and
negative symptoms, such as drug use or premorbid adjustment be-
cause we did not have access to these data.
Previous studies have noted considerable variation in ﬁrst epi-
sode psychosis cohorts (Schmitz et al., 2007), for example in: par-
ticipant characteristics; instruments to assess symptoms;
measures of DUP; and deﬁnitions of DUP. In this meta-analysis we
included observational studies as well as interventional studies.
No interventional studies targeting negative symptoms were in-
cluded. Some studies rely entirely on the patients' own reports
and thus reﬂect the onset of the subjective experiences of psychosis
while most studies have validated ratings of DUP by including inter-
views with family members, hospital records and reviews after one
year of follow-up. Despite these problems, this analysis detected
only a mild to moderate degree of statistical heterogeneity between
studies, at a level that was not sufﬁcient to undermine the main
ﬁndings. We conducted a funnel plot in order to test publication
bias. The plot shows the presence of symmetry for all analysis.
Since the sampling error is random, this underpins the idea that
there is no substantial publication bias.
In summary, the relationship between DUP and negative
symptoms has been underestimated, and is in fact strong and
persistent. A DUP of less than 9 months appears to be a strong
predictor of improvement of negative symptoms, while most pa-
tients with a DUP longer than 9 months show persistent nega-
tive symptoms. It is unknown to what extent reducing DUP
will improve outcome. However efforts to shorten DUP might
decrease negative symptom severity as has been done in the
Scandinavian TIPS study (Melle et al., 2008). The absence of sub-
stantially effective treatments for negative symptoms supports
preventive interventions with the potential to ameliorate nega-
tive symptoms, e.g. by reducing DUP.Role of funding source
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Nynke Boonstra designed the study and wrote the protocol together with Rianne
Klaassen and Lex Wunderink. Together they performed the literature searches and
analysis. Max Marshall supported the analysis and interpretation, and Sjoerd Sytema,
Lieuwe de Haan and Durk Wiersma read and revised the manuscript. All authors con-
tributed to and have approved the ﬁnal manuscript.
17N. Boonstra et al. / Schizophrenia Research 142 (2012) 12–19Conﬂict of interest
All authors declare that they have no conﬂicts of interest.
Acknowledgment
The authors wish to thank the research teams who were so kind to send us their
raw data. In particular we want to thank: Jean Addington, Thomas Barnes, Evelyn
Bromet, Eric Chen, Eadbhard O'Callaghan, John Stirling, Richard Drake, Lena Flyckt,
Krystyna Gorna, Krystyna Karacz, Lone Petersen, Meredith Harris, Rahul Manchanda,










DUP deﬁnition Instrument used to
determine DUP
Addington et al. (2004) 240 Canada – 36 PANSS From the time the individual ﬁrst described the
onset of any positive sx that could be rated as
4 or more on the PANSS until the ﬁrst effective
treatment was initiated.
IRAOS
Barnes et al. (2000) and
Subramaniam et al. (2007)
98 United Kingdom 16–55 12 SANS Onset of psychotic sx to ﬁrst treatment with
antipsychotic medication.
NS
Black et al. (2001) 21 Canada – 6 PANSS Onset of positive psychotic sx (score of ≥4 on
any of the positive subscale items in the PANSS,
these sx must have lasted throughout the day
for several days or appeared several times a week)
until the beginning of treatment with antipsychotic
medication.
IRAOS
Chen et al. (2005) 93 Hong Kong 18–55 36 PANSS Onset date for the earliest psychotic sx. IRAOS
Clarke et al. (2006) 152 Ireland 12> 96 PANSS First noted psychotic symptoms to presentation to
the psychiatric services for initiation of adequate
treatment of a psychotic illness.
SCID
Craig et al. (2000) 354 United States 15–60 24 SANS Occurrence of the ﬁrst clear psychotic symptom to
ﬁrst psychiatric hospitalization.
SCID
Crespo-Facorro et al. (2007) 61 Spain 15–60 36 SANS First continuous (present most of the time) psychotic




Cullberg et al. (2002)
175 Sweden 18–45 60 BPRS First psychotic sx until the ﬁrst contact with
psychiatric services.
SCID
de Haan et al. (2000) (61) 88 The Netherlands Adolescents 72 PANSS First onset of psychotic sx until start of antipsychotic
medication (for a minimum of 6 weeks).
NS
Drake et al. (2000) 255 United Kingdom 16–64 18 PANSS Onset of delusions and hallucinations. NS
Gorna et al. (2008) 86 Poland Adults 60 PANSS Onset of ﬁrst psychotic symptoms to the initiation
of antipsychotic treatment
ICD 10
Harris et al. (2005) 318 Australia 16–45 96 SANS Onset of psychosis to initiation of treatment. RPMIP
Ho et al. (2000) 74 United States – 6 SANS Onset of ﬁrst sx to the initiation of neuroleptic
treatment
CASH+PSYCH-base
Larsen et al. (2000) 43 Norway 15–55 12 PANSS Onset of psychotic sx to hospitalization for psychosis
or initiation of adequate treatment.
SCID
Malla et al. (2007) 172 Canada 16–50 12 PANSS Onset of psychotic sx to the time of initiation of
continuous antipsychotic treatment, plus any
periods of psychosis previously experienced
and spontaneously remitted.
CORS
Malla et al. (2003) 153 Canada 16–50 36 SANS, Initial onset of psychosis to treatment
(antipsychotic medication of a dosage that should
actually lead to a signiﬁcant response in most
patients for a period of time (4 weeks)).
SCID
Manchanda et al. (2005) 122 Canada 16–50 24 SANS Onset of clear symptoms of psychosis to the initiation
of antipsychotic medications.
CORS
Melle et al. (2005) 301 Scandinavia 18–65 24 PANSS Onset of psychosis (ﬁrst week with sx corresponding
to a PANSS score of ≥4 or on positive subscale items
1, 3, 5 or 6 or on the general subscale item 9) until
start of adequate treatment (structured treatment
with antipsychotic medications or hospitalization in a
highly staffed psychiatric ward to manage psychotic sx,).
SCID
Montague et al. (1989) 109 United Kingdom 16–50 120 SANS First onset of positive symptoms to index admission PSE-9
Oosthuizen et al. (2005) 57 South Africa 16–55 24 PANSS Onset of overt hallucinations or delusions, up to the
initiation of treatment with antipsychotic medication.
SCID
Petersen et al. (2005) 578 Scandinavia 18–45 24 SANS Appearance of at least one psychotic sx until initiation
of adequate treatment
SCAN & IRAOS.
Sim et al. (2004) 278 Singapore 18–40 24 PANSS Onset of psychotic sx and the time that treatment
was initiated.
SCID-P
Ucok et al. (2006) 148 Turkey 15–45 12 SANS Onset of the ﬁrst positive sx to the ﬁrst hospitalization. SCID e.
Verdoux et al. (2001) 65 France b60 24 PANSS Onset of positive symptoms to ﬁrst admission. MINI
Vyas et al. (2007) 40 United Kingdom Adolescents 48 PANSS Age of onset of psychosis tp age at initiation of
antipsychotic treatment.
SCID/KID-SCID
SANS Onset of psychotic symptoms to service entry. RPMIPWade et al. (2005) 126 Australia 15–30 15References
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